NYSE: $HAE
In the rapidly evolving field of cardiac electrophysiology, the precision of venous access closure is as critical as the primary procedure itself. Haemonetics Corporation recently announced compelling new clinical evidence regarding its VASCADE MVP® XL venous vascular closure system, marking a significant milestone for procedural safety and efficiency in large-bore venous access.
The Study: Comparative Efficacy and Safety
Published in the Journal of Cardiovascular Electrophysiology, the study titled “VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Single-Center Experience on Efficacy and Complications” provides a retrospective look at 574 patients. The research compared the performance of the standard VASCADE MVP system against the newer VASCADE MVP XL in procedures such as catheter ablation for atrial arrhythmia and left atrial appendage (LAA) closure.
The results were clear: the VASCADE MVP XL demonstrated superior performance in large-bore scenarios. Notably, the study reported a 0% rate of bleeding complications, highlighting a consistent and robust safety profile that supports efficient hemostasis during these high-stakes procedures.
Meeting the Demands of Modern Electrophysiology
As medical technology advances, so do the tools used by clinicians. In March 2026, the FDA granted expanded labeling for the VASCADE MVP XL to include procedures utilizing 10-14F inner diameter and up to 17F outer diameter (OD) procedural sheaths. This expansion makes the system an essential companion for market-leading pulsed field ablation (PFA) technologies, such as the FARAPULSE® system, and LAA closure devices like the WATCHMAN TruSteer®.
Dr. Jan Hartmann, Senior Vice President and Chief Medical Officer at Haemonetics, noted that this expanded indication arrives at a pivotal time. “By enabling reliable venous closure in large-bore procedures, VASCADE MVP XL helps electrophysiology teams deliver safe, effective care across hospital-based labs and increasingly time- and cost-conscious outpatient settings, including ambulatory surgery centers,” said Dr. Hartmann.
Clinical Evidence and Future Outlook
The FDA approval was bolstered by the AMBULATE EXPAND trial, which validated the safety and effectiveness of the device in 17F OD procedures. Further bolstering this evidence, a prospective ultrasound sub-study recently published in Heart Rhythm O2 offered imaging-based assessments of closure sites. These findings demonstrated encouraging vascular healing in a population of high-risk, fully anticoagulated patients.
For professionals looking to stay at the forefront of these clinical advancements, Haemonetics is hosting a session titled “Efficient Workflows for AF Ablation: New Technologies and Sites of Service” at the Heart Rhythm Society’s Heart Rhythm 2026 conference in Chicago. The session, scheduled for Saturday, April 25, 2026, will feature further discussion on the clinical data surrounding the VASCADE MVP XL.
As the electrophysiology landscape shifts toward next-generation ablation technologies, the ability to rely on consistent, proven venous closure systems remains a cornerstone of successful patient outcomes.